GH Research Announces Pricing of $150 Million Public Offering

Group 1 - GH Research PLC has announced a public offering of 10,000,000 ordinary shares at a price of $15.00 per share, aiming for total gross proceeds of approximately $150 million [1] - The offering is expected to close on February 6, 2025, subject to customary closing conditions [1] - GH Research PLC has granted underwriters a 30-day option to purchase an additional 1,500,000 ordinary shares at the public offering price [1] Group 2 - Cantor, Stifel, and RBC Capital Markets are acting as joint book-running managers for the offering, while Canaccord Genuity and Citizens JMP are co-lead managers [2] Group 3 - GH Research PLC is a clinical-stage biopharmaceutical company focused on developing treatments for depression, specifically targeting treatment-resistant depression (TRD) with its proprietary mebufotenin therapies [7]